Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
Scientists at St. Jude Children's Research Hospital have demonstrated a more effective treatment for bacterial pneumonia following influenza.
Today's decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to approve the reclassification of azithromycin for the treatment of chlamydia infection will mean convenient and effective care for patients, said the Royal Pharmaceutical Society of Great Britain (RPSGB).
For the first time sufferers in the UK from the common sexually transmitted infection (STI) chlamydia will be able to buy an antibiotic to treat the infection over-the-counter (OTC), without a prescription from a doctor.
Researchers at the University of Illinois at Chicago have discovered how some bacteria can survive antibiotic treatment by turning on resistance mechanisms when exposed to the drugs.
One or two rounds of high coverage mass treatment with azithromycin, rather than the annual treatment recommended by the World Health Organisation, may be enough to eliminate the eye disease trachoma in communities with moderate levels of infection.
Changing the administration of the antibiotic azithromycin from once to twice a year in villages in Ethiopia substantially reduced eye infections in preschool children caused by chlamydia, which causes the serious, contagious eye disease trachoma, according to a study in the February 20 issue of JAMA.
Mylan Laboratories Inc. ( NYSE:MYL ) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDAs) for Azithromycin Tablets, 250 mg and 500 mg.
A Cambridge University team have developed a simple "dipstick" test to detect the eye infection trachoma, a disease spread by flies, which could potentially help save the sight of millions around the world.
A Johns Hopkins Medicine study finds that a single dose of the oral antibiotic azithromycin taken after trichiasis eye surgery can reduce the frequency with which eyelashes turn back in and abrade the eye.
Treating trachoma, an eye infection that can lead to blindness, with a single mass antibiotic distribution in Ethiopian communities with high prevalence of infection is not effective in eliminating the disease
The study, by Australian researchers Catriona Bradshaw, MD, and colleagues at the Melbourne Sexual Health Centre, is the first major case-control study to simultaneously address all currently hypothesized causes of NGU.
"The big three" infections AIDS, TB and malaria have caught the world's attention but other disabling and fatal infectious diseases in Africa are being ignored, say three eminent tropical disease researchers in the international health journal PLoS Medicine.
Using X-ray crystallography, researchers at Yale have "seen" the structural basis for antibiotic resistance to common pathogenic bacteria, facilitating design of a new class of antibiotic drugs, according to an article in Cell.
Howard Hughes Medical Institute researchers chiseling away at the problem of antibiotic resistance now have a detailed explanation of how the drugs' main cellular target in bacteria evolves to become resistant to some of these medications.
Taking antibiotics weekly for one year does not reduce the risk of a heart attack or other cardiac event for patients with stable coronary artery disease, according to a study funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health. It is published in the April 21, 2005, edition of the New England Journal of Medicine.
The problem of increasing antibiotic resistance in cases of Streptococcus pneumoniae, a major cause of pneumonia, meningitis and sepsis, was dramatically reversed following the licensing and use of a new conjugate vaccine for young children in February 2000, according to research conducted at Emory University, the Atlanta Veterans Affairs Medical Center, the Centers for Disease Control and Prevention, and the Georgia Division of Public Health.
In an editorial to be published in The New England Journal of Medicine, researchers at Johns Hopkins offer their support for a study which shows that providing faster, more direct access to antibiotics for partners of newly infected patients reduces re-infection rates and spread of sexually transmitted diseases, such as gonorrhea and Chlamydia, compared to standard practice.
The New England Journal of Medicine published today a study entitled "Mass Treatment with Single-Dose Azithromycin for Trachoma."
Pfizer Inc.'s new investigational microsphere formulation of azithromycin, which is dosed as a one-time-only oral antibiotic, is comparable to other frequently prescribed treatments for some of the most common respiratory tract infections in adult patients.